Nortriptyline for Severe Neuropathic Pain
Start nortriptyline at 25 mg orally at bedtime and titrate by 25 mg every 3-7 days up to 75-100 mg daily (maximum 150 mg/day), monitoring for therapeutic plasma levels of 50-150 ng/mL and checking an ECG in patients over 40 years before initiation 1, 2.
Initial Dosing and Titration
Begin with 25 mg once daily at bedtime to minimize sedation and anticholinergic side effects 1. Increase the dose by 25 mg increments every 3-7 days based on tolerability. The target therapeutic range is typically 75-100 mg daily, though doses above 100 mg require plasma level monitoring 1.
For elderly patients, use lower starting doses of 30-50 mg/day in divided doses and titrate more cautiously, as they are at higher risk for cardiotoxicity and accumulation of the active metabolite 10-hydroxynortriptyline 1.
Maximum dose is 150 mg/day - doses above this are not recommended and provide no additional benefit 1.
Timeline for Adequate Trial
Allow 6-8 weeks total, including 2 weeks at the maximum tolerated dose, before determining treatment failure 2. This extended timeline is critical because tricyclic antidepressants require time to achieve full analgesic effects through neuronal plasticity mechanisms.
Required Monitoring
Pre-Treatment
- ECG screening is mandatory for all patients over 40 years to identify baseline conduction abnormalities 2
- Screen for cardiovascular disease, glaucoma, urinary retention, seizure history, and bipolar disorder risk 1
During Treatment
- Plasma level monitoring when doses exceed 100 mg/day - maintain levels between 50-150 ng/mL 1
- Higher plasma concentrations correlate with increased adverse effects without additional benefit 1
- Monitor closely during the first few months for suicidality, especially in younger patients, and at any dose changes 1
- Watch for cardiac symptoms (palpitations, syncope), as myocardial infarction, arrhythmias, and strokes have occurred 1
Combination Therapy for Severe Pain
When monotherapy provides inadequate relief, combining nortriptyline with gabapentin or morphine produces superior pain reduction compared to either drug alone 3, 4.
The nortriptyline-gabapentin combination reduced pain scores from 5.4 to 2.3 (versus 3.2 for gabapentin alone and 2.9 for nortriptyline alone) 4. Similarly, nortriptyline-morphine combination achieved pain scores of 2.6 versus 3.1 for nortriptyline alone 3.
For combination therapy, use lower doses of each agent (e.g., nortriptyline 55 mg + morphine 49 mg daily) to minimize additive side effects while maintaining efficacy 3.
Critical Safety Considerations
Cardiac toxicity is the primary concern - prescribe with extreme caution in patients with ischemic heart disease or ventricular conduction abnormalities, limiting doses to under 100 mg/day when possible 2. Nortriptyline produces sinus tachycardia and prolongs conduction time 1.
Anticholinergic effects are dose-dependent and include:
- Dry mouth (49-58% at therapeutic doses) 3, 4
- Constipation (5% with nortriptyline alone) 3
- Urinary retention risk in susceptible patients 1
- Glaucoma exacerbation 1
Avoid abrupt discontinuation - taper gradually to prevent withdrawal symptoms. Prescribe the smallest quantity consistent with good management to reduce overdose risk 1.
Drug interactions: Blocks antihypertensive effects of guanethidine; potentiates thyroid medication effects leading to arrhythmias; alcohol combination increases suicidal risk 1.
Common Pitfalls to Avoid
- Don't abandon treatment prematurely - the full 6-8 week trial is essential before declaring failure 2
- Don't exceed 150 mg/day - no additional benefit and increased toxicity 1
- Don't skip ECG screening in older patients - cardiac events are a real risk 2, 1
- Don't use as monotherapy if partial response - add gabapentin or consider morphine combination for severe refractory pain 2, 3, 4
- Don't ignore plasma levels above 100 mg/day - therapeutic drug monitoring prevents toxicity 1
Position in Treatment Algorithm
Nortriptyline is a first-line agent for neuropathic pain alongside other tricyclic antidepressants, SNRIs, and gabapentinoids 2. It works by blocking norepinephrine and serotonin reuptake, with the increased monoamine concentration providing central analgesic effects 5, 6. Additionally, nortriptyline reduces pro-inflammatory cytokine production (particularly TNF-α) and enhances inhibitory neurotransmission in pain pathways 7, 6.
For severe neuropathic pain not responding to monotherapy, escalate to combination treatment rather than switching agents 2, 4.